



Osteoporosis in 10 years time: a glimpse into the future of osteoporosis

Giovanni Adami¹, Angelo Fassio, Davide Gatti, Ombretta Viapiana, Camilla Benini, Maria I. Danila, Kenneth G. Saag² and Maurizio Rossini¹

Ther Adv Musculoskel Dis

2022, Vol. 14: 1–14

DOI: 10.1177/
1759720X221083541

© The Author(s), 2022.
Article reuse guidelines:
sagepub.com/journals-
permissions

Abstract: Patients living with osteoporosis are projected to increase dramatically in the next decade. Alongside the forecasted increased societal and economic burden, we will live a crisis of fractures. However, we will have novel pharmacological treatment to face this crisis and, more importantly, new optimized treatment strategies. Fracture liaison services will be probably implemented on a large scale worldwide, helping to prevent additional fractures in high-risk patients. In the next decade, novel advances in the diagnostic tools will be largely available. Moreover, new and more precise fracture risk assessment tools will change our ability to detect patients at high risk of fractures. Finally, big data and artificial intelligence will help us to move forward into the world of precision medicine. In the present review, we will discuss the future epidemiology and costs of osteoporosis, the advances in early and accurate diagnosis of osteoporosis, with a special focus on biomarkers and imaging tools. Then we will examine new and refined fracture risk assessment tools, the role of fracture liaison services, and a future perspective on osteoporosis treatment.

Keywords: bone mineral density, fractures, future perspective, osteoporosis

Received: 19 November 2021; revised manuscript accepted: 7 February 2022.

Introduction

Osteoporosis is a chronic disease characterized by bone fragility and fractures. Osteoporosis represents a relevant global public health problem, which is projected to increase in magnitude in the next 10 years. Fortunately, substantial advances in the diagnosis and treatment of osteoporosis have emerged in the last decade and we have now the knowledge and instruments to tackle the ongoing osteoporosis crisis. In the present review, we will mainly focus on forecasts on the epidemiology of and costs related to osteoporosis in the next decade and we will discuss on the future of osteoporosis diagnosis, fracture risk assessment, and treatment.

Epidemiology and costs of osteoporosis in 10 years from now

Osteoporosis represents a major worldwide clinical, societal, and economical challenge. Osteoporosis prevalence and burden are projected to increase in the following years, mainly in relation to the aging

of the population. Scorecard for Osteoporosis in Europe (SCOPE) is an international project aimed to determine the burden of osteoporosis across Europe.¹ The SCOPE panel, which was first established in 2010 and updated in 2021, evaluates the information regarding osteoporosis in 29 countries through structured questionnaires (27 European countries, the United Kingdom, and Switzerland).² The SCOPE data provides a comprehensive picture of what is happening nowadays in Europe in terms of osteoporosis burden and can help forecast what will happen in the next decade. The total direct costs related to osteoporosis care (fragility fracture treatment and pharmacological costs) amounted to an astonishing cost of €37.4 billion in 2010, which increased to an even greater amount in 2019 (€56.9 billion, +64%). This observed increase was consistent with 50% increase in costs by 2025 proposed in 2007.³ In their study, Burge *et al.* used Markov decision models to estimate fracture costs over two decades (2005–2025). What is noteworthy and, at the same time, disheartening, is that despite the cost of osteoporosis care, the pharmacological

Correspondence to:

Giovanni Adami
Rheumatology Unit,
University of Verona, Pz
Scurio 10, 37134 Verona,
Italy.
adami.g@yahoo.com;
giovanni.adami@univr.it

Angelo Fassio
Davide Gatti
Ombretta Viapiana
Camilla Benini
Maurizio Rossini
Rheumatology Unit,
University of Verona,
Verona, Italy

Maria I. Danila
Kenneth G. Saag
Division of Clinical
Immunology and
Rheumatology, The
University of Alabama
at Birmingham,
Birmingham, AL, USA



and assessment costs decreased from €2.1 billion in 2010 to €1.6 billion in 2019. Moreover, the costs of Quality Adjusted Life Years (QALYs) lost were not included in the latter estimation of costs. Indeed, the overall costs were even higher when QALYs were included. QALYs lost costs amounted to an overwhelming total of €112.9 billion, resulting in a €169.8 billion of direct and indirect costs related to osteoporosis in 2019. The disparity between costs related to fragility fracture care and pharmacological costs is startling and becomes even more evident when compared with other noncommunicable diseases. Indeed, the pharmacological treatment for cardiovascular diseases represented approximately one quarter of the total expenditures, a proportion that is considerably higher than that for osteoporosis (2.8%).

Osteoporosis is estimated to affect more than 30 million persons in Europe and a similar number of individuals in the United States.^{4,5} The vast majority of these are women. However, studies at population level could underestimate the true prevalence of a silent disease such as osteoporosis. Indeed, osteoporosis prevalence strictly depends on screening availability. Screening strategies with standard dual-energy X-ray absorptiometry (DXA) in women aged more than 50 years have been implemented in most western countries but remain underutilized in many other developing countries.⁶ Moreover, osteoporosis in men is still largely underdiagnosed, and the diagnosis is commonly made in the presence of a fragility fracture. Concerningly, the proportion of patient living with osteoporosis worldwide is increasing.

Fragility fractures are the consequence of osteoporosis and reducing their incidence represents the primary outcome for all interventions. More than 4 million fractures have been reported each year in Europe in the last 5 years. These numbers are projected to increase substantially in the next 10 years. In fact, the SCOPE analysis has estimated that the overall number of fractures will increase by 20% by 2035. In addition, simulation models have been used to predict the future burden of fragility fracture. A recent study by Cui *et al.* showed that, in China, the annual number of fragility fracture will increase by 135% by 2040, while the proportion of population >50 years will increase by approximately 100%. This increase is partially preventable by adoption of relatively simple and cost-effective strategies, such as increased awareness about the availability

of pharmacological options and interventions aimed to improve treatment adherence.^{7–10}

In summary, the burden of osteoporosis and fragility fractures is projected to increase at a dramatic pace in the next decade taking in consideration the effect of the aging of the population alone. Of concern, there are individual and environmental factors that can further augment this trend. As an example, obesity and diabetes, which have increased in prevalence worldwide, have been largely associated with higher risk of fracture independently from bone mineral density (BMD).^{11–13} Sedentary lifestyle in younger individuals has also been associated with increased risk of osteoporosis later in life.¹⁴ Moreover, environmental air pollution, a well-known issue for present and future generations,¹⁵ has been linked with a substantial increase in the risk of osteoporosis and fractures.^{16,17} However, effective interventions exist to help mitigate the challenges posed by increased osteoporosis prevalence. Lifestyle modifications for healthy bones should be advised for all populations, screening strategies should be implemented and harmonized across countries, treatment accessibility should be improved, and treatment adherence should be encouraged.

Advances in early and accurate diagnosis of osteoporosis

Advances in imaging techniques of osteoporosis

For epidemiological purposes, osteoporosis was defined by World Health Organization (WHO) as ‘BMD lower than -2.5 SD below the peak bone mass of young healthy adults’.¹⁸ While the WHO definition is widely utilized in daily clinical practice to make a diagnosis of osteoporosis, it should be recognized that it is plagued by several disadvantages. The most important shortcoming of defining osteoporosis merely on BMD levels is that we may miss this diagnosis in all those patients who fracture at *T*-scores above -2.5. Indeed, approximately half of all fragility fractures occurs in patients with osteopenic or even normal *T*-scores.⁵ To overcome this fallacy, we commonly incorporate clinical characteristics to BMD for estimating the risk of fracture of an individual. Several clinical risk factors are included in widely available algorithm, such as the Fracture Risk Assessment Tool (FRAX),^{19,20} which provides an estimation of the absolute risk over the time of the patient but do not, however, capture all the determinants of fractures. As an

example, the FRAX and other similar algorithms do not account for bone strength or bone microarchitecture. The NIH, in 2001, has further expanded the definition of osteoporosis by adding the 'bone strength' concept, which is largely, but not entirely, dependent on BMD.²¹ This is of particular importance in diseases that deteriorate bone quality without affecting bone quantity. As an example, in glucocorticoid-induced osteoporosis (GIOP), the fracture threshold is lower than in postmenopausal osteoporosis, which means that patients fracture at osteopenic or even normal *T*-scores.²² Diabetes alters the bone microarchitecture and, therefore, is characterized by an increased risk of fracture independently of BMD levels.¹¹ However, while there are approaches to assess bone microarchitecture or bone flexibility and elasticity,^{23–26} measurements of bone strength are not widely available in clinical practice for diagnosing bone fragility long before the BMD criteria of osteoporosis are met.

One of the most promising tools for estimating bone strength is the trabecular bone score (TBS). The TBS is calculated using an analytical tool that processes the gray-level texture of normal DXA scans to estimate trabecular microarchitecture.²⁶ TBS can be easily implemented in most of the DXA instruments. The Manitoba bone density program was one of the groups that pioneered the role of TBS in fracture prediction.²⁷ Leslie and colleagues demonstrated that TBS provided an incremental improvement in fracture risk estimate; the authors analyzed data on more than 30,000 women and showed that the TBS was inversely correlated with fracture risk, independently from clinical risk factors and femoral neck BMD. In a meta-analysis of X cohort studies on TBS in 2015, TBS was found to be significant predictor of fracture independently from FRAX.²⁸ Importantly, this finding was consistent across independent and international cohorts that included racial and ethnic diverse populations. An adjusted version of the FRAX that accounts for TBS is now available for clinical purposes.²⁹ However, the TBS is proprietary software which is not systematically applied to DXA scans, principally for its costs.

Hip-axis length (HAL), hip-strength analysis (HSA), and finite element analysis (FEA) are other methodologies that, similarly to TBS, can be obtained from DXA analysis. The HAL, which is defined as the length from the great trochanter and the pelvic brim, has been positively correlated

with the risk of hip fracture.³⁰ The longer the HAL the higher the risk of fracture is, independently from other clinical and densitometric risk factors. The mechanism underpinning this increased risk is most likely related to the greater protrusion of the trochanter, which can result in a higher susceptibility of impact in sideways falls. The HSA is an imaging post-processing software that was first developed in 1990 by Beck *et al.*³¹ The HSA derives from the analysis of the femoral neck cross-sectional area (CSA) and cross-sectional moments of inertia (CSMI). The HSA estimates the cortical stability in buckling and represents an index of structural rigidity. The ability of HSA in estimating fracture risk has been assessed in few small clinical studies. Addition of HSA to standard BMD measurements can improve the prediction of hip fracture.^{32,33} Of note, HSA parameters are not influenced substantially by antiosteoporotic treatments and should be considered a nonmodifiable risk factor for fractures.³² FEA is another computerized method that estimates the microarchitectural geometry of the hip. In particular, FEA can be used to study the behavior of bone in relation to mechanical loading. FEA has been largely applied in computer tomography but is now available in DXA too, making this technique more accessible. However, despite the enthusiasm around these techniques, the International Society for Clinical Densitometry (ISCD) did not endorse their use in routine clinical practice as recent as 2015³⁴ based on the scarce data about measurement reproducibility available at that time. In the last years, new imaging processing software have been released and the predictive power of FEA simulations models are getting better; however, large, confirmatory, clinical studies are still lacking.³⁵

Radiofrequency echographic multi spectrometry (REMS) is an innovative approach that uses ultrasound to analyze BMD.³⁶ Raw and unfiltered ultrasound images of lumbar spine and femoral neck are analyzed by a software to provide a DXA-equivalent BMD value. The REMS effectiveness in identifying subjects at risk of fracture has been studied in a recently published longitudinal study.³⁷ More than 1500 patients underwent a DXA and REMS investigation and were followed up to 5 years. DXA and REMS *T*-score values were highly correlated, and the fracture prediction ability was similar for both vertebral, hip and non-vertebral, non-hip fractures. Moreover, REMS can provide an estimation of bone strength (fragility index) which is independent from BMD and

has been shown to effectively predict the fracture risk.³⁸ REMS has recently received the endorsement for clinical use of the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO).³⁹

High-resolution peripheral quantitative computed tomography (HRpQCT) is an alternative imaging technique that can provide both quantitative and qualitative information regarding the skeleton. HRpQCT parameters, such as cortical thickness or FEA, showed to effectively predict the fracture risk independently from FRAX score and areal BMD measured by DXA alone.²⁵ Moreover, new advances in the CT technology have reduced the amount of ionizing radiation making this technique attractive for routinely assessing bone quality and bone quantity in patients with osteoporosis. However, HRpQCT is an expensive technology and as such its use might be limited in clinical practice. Table 1 shows the imaging techniques for bone density and structure evaluation.

Advances in biomarkers of osteoporosis

Micro RNA (miRNA) and long-non-coding RNA (lncRNA) are novel markers and targets of great interest in the field of osteoporosis.⁴⁰ miRNA and lncRNA can control gene expression and are widely recognized as crucial regulators of cell development and differentiation. miRNA and lncRNA are involved in a variety of cellular pathways.⁴¹ These small RNA molecules are responsible for the differentiation of bone cells by regulating gene expression. miRNA-103a can directly inhibit gene expression that is correlated with osteoblasts differentiation. Interestingly, mechanical unloading is associated with the overexpression of miRNA-103a, which, in turn, results in a strong inhibition of bone formation. Consequently, targeting miRNA-103a with antagomir-103a can rescue the osteoporosis caused by immobilization and mechanical unloading.⁴² miRNA and lncRNA are versatile markers of disease and, more interestingly, they represent a novel therapeutic target. However, targeting miRNA and lncRNA is still a futuristic prospect, nowadays only limited to *in vitro* and animal studies. Nonetheless, this field has expanded considerably in the last decade and the promise of having novel agents that target miRNA in the next 10 years is now realistic.

In summary, in the next decade, we may have routine access to novel markers of bone fragility,

such as TBS, FEA, and HR-pQCT, which will help the early diagnosis of osteoporosis. Early diagnosis is crucial to target the right intervention in the right patient population. Indeed, highly sensitive and specific diagnostic tools are key for 'precision medicine' that can enable implementing highly efficacious interventions in those patients who are likely to experience fractures. Novel analytical tools will help refine fracture risk assessment, especially in those patients border line for pharmacological interventions.

Advances in noninvasive diagnosis of osteoporosis

As mentioned before, the densitometric definition of osteoporosis has several pitfalls, mainly due to uncaptured fragility. Indeed, mechanical testing of bone properties in human might represent a novel approach for osteoporosis definition.⁴³ As an example, external mechanical loading has been widely used in animal studies but some applications, such as dynamic hydraulic stimulation, might be envisioned for human applications too.⁴⁴ In addition, magnetic resonance imaging (MRI) might be considered in the future as it has been shown to effectively differentiate primary mineralization defects (e.g. osteomalacia) from structure defects (e.g. osteoporosis), possibly allowing new, cutting-edge, virtual biopsies.⁴⁵

Novel fracture risk assessment tools

As noted above, algorithms for fracture risk assessment are currently widely used in clinical practice to estimate fracture risk.^{19,20,46} Such algorithms are based on fixed multipliers of risk derived from cohort studies. This approach might be limited to the relatively small number of risk factors considered by these algorithms. A novel and promising method might, however, overcome this limitation. Machine learning and deep learning approaches are rapidly revolutionizing and improving our ability to predict health outcomes.⁴⁷ Machine learning is a computer-based approach used to generate a predictive algorithm based on training datasets; this approach at first sight might appear similar to what has been done by standard predictive tools since today. However, machine learning approach uses complex datasets derived from electronic medical records that enable consideration of a significant number of risk factors simultaneously. By doing so, machine learning algorithms not only consider more risk factors in the estimation of risk than standard

algorithms but also factors that are usually not thought traditionally to be associated with the outcome. Furthermore, machine learning algorithms continuously learn from data and become more refined with each iteration. This latter aspect represents a major advantage since fracture risk assessment can be tailored to a specific subpopulation and can be informed by treatment modalities. Machine learning approaches have been shown to effectively predict fracture risk and to predict BMD response following antiosteoporotic treatment.^{48–51} The major advantages of the machine learning approaches over standard risk algorithms are hundreds of clinical variables are considered, prediction of risk is automatized based on available data and, more importantly, this approach can be easily applied and automatized to hospital that use electronic medical records, reducing the burden on clinicians. Tanphiriyakun *et al.*,⁴⁸ for example, developed a computational model from 8981 clinical variables that effectively predicted BMD changes after treatment with antiosteoporotic medications. In other words, this approach can estimate patients' response to treatment based on their characteristics better than physicians. Indeed, it has been estimated that guiding the pharmacological treatment with this model can improve the average treatment response by 9.54%. This and other novel computer-based approaches can guide the therapy choice in osteoporosis and will help personalize the treatment.

Fracture liaison services

Having had a prior fragility fracture is the main risk factor for new fractures and secondary prevention is crucial for fracture incidence reduction at a population level. The risk is exceptionally high in the 2 years following the index fracture; nonetheless, fewer than 20% of patients with a fragility fracture are assessed and treated appropriately for osteoporosis.⁵² This treatment gap has been the focus of discussions among bone specialists for the past decade. Identifying, assessing, and treating patients with an acute fragility fracture has therefore become the crucial link in the chain of osteoporosis care. To address this care gap, health centers around the world have developed integrated osteoporosis management teams aimed to recognize and promptly treat osteoporotic fractures. These services, also known as fracture liaison services (FLS), are rapidly proliferating in Europe, but to a lesser degree in the United States given the complex multi-payer healthcare environment.⁵³ It is

now clear that high-intensity FLS (which comprise identification, investigation, and initiation of therapy) have been successful in reducing the incidence of new fractures.⁵⁴ Moreover, cost-effectiveness analyses of FLS showed gains in quality-adjusted life years (QALY) for expenses below the willingness to pay thresholds.⁵⁵ A recently published meta-analysis showed that the implementation of FLS is associated with lower probability of subsequent fractures with a trend toward mortality reduction.⁵⁴ Evidence mostly came from indirect comparisons between hospitals with and without FLS and from the comparison between pre-FLS *versus* post-FLS periods in the same hospital. Majumdar *et al.*⁵⁶ in 2018 conducted a pragmatic randomized controlled trial comparing two different FLS strategies. In this trial, 361 patients suffering from an upper extremity fracture were randomized to either a low-intensity FLS (phone call encouraging referral to family physician) or a high-intensity FLS (phone call arranging a visit, laboratory, and BMD tests). The primary outcome of the study was the proportion of patients initiating bisphosphonates within 6 months from the fracture. At 6 months approximately 50% of patients in the high-intensity FLS arm started on bisphosphonates compared with slightly less than 30% in the low-intensity arm. The International Osteoporosis Foundation (IOF) and the American Society for Bone and Mineral Research (ASBMR) strongly encourage the promotion of FLS in hospital facilities; moreover, IOF have initiated the 'capture the fracture' program in 2013, which have provided support and recognition to more than 600 FLS across 49 countries worldwide. The IOF 'capture the fracture' initiative is now available for free peer-review assessment of FLS.

In the future, FLS will be likely to be harmonized across hospitals and will likely leverage automated identification of persons who fracture and their referral to bone specialists for care. Natural language processing algorithm could help recognize fragility fractures from clinical and imaging notes in electronic medical records and clinical decision support algorithms will help define the appropriate investigations for each patient. Moreover, harmonized outcomes reporting across FLS will help define the standard of care for FLS and will help refine and improve this health system intervention. Nevertheless, in many countries worldwide, there is still a lack of awareness for osteoporosis and still FLS are not implemented in the routine clinical practice yet. We should, therefore, acknowledge that it is a long way to the top.

Future perspective on osteoporosis therapies

Pharmacological treatment for osteoporosis began more than 70 years ago with estrogens in postmenopausal osteoporosis; later, in the early 1970s, bisphosphonates were first prescribed for the treatment and prevention of osteoporosis. During the ensuing 40 years, many novel pharmacological agents have been tested and several of these have been approved for the treatment and prevention of osteoporosis to reduce the risk of fracture. Bisphosphonates still represent the most commonly used therapy for osteoporosis worldwide, but therapeutic armamentarium includes another potent antiresorptive drug (denosumab), two bone anabolics (teriparatide and abaloparatide), and a novel agent with a dual anabolic/antiresorptive mechanism of action (romosozumab). However, since the use of bone anabolics and romosozumab are restricted in duration of therapy and since a pharmacologic treatment is likely to be necessary lifelong, a sequential approach is crucial and should be planned in advance. Indeed, it is likely that, in the future, discussions among bone experts will focus more on the sequential approach to treatment, as more scientific knowledge is accumulating rapidly on this topic.

Anabolic agents can build up new bone and possibly reverse the osteoporotic state, but their use is limited to 24 months during lifetime currently and a potent antiresorptive agent is recommended at discontinuation. The PaTH (Parathyroid Hormone and Alendronate) study first investigated the opportunity of bisphosphonate treatment after 1 year of recombinant parathyroid hormone 1–84.⁵⁷ Considering only subjects who took parathyroid hormone 1–84 followed by alendronate or placebo, those that received alendronate maintained or increased the BMD at lumbar spine and femur, while women that received placebo lost most of the beneficial effect attained during the first 12 months of treatment. Again, in the ACTIVEExtend trial, subjects received 2 years of abaloparatide followed by alendronate,⁵⁸ and BMD levels achieved during the anabolic phase of the study were further improved during the alendronate phase. The denosumab and teriparatide transition in postmenopausal osteoporosis (DATA-SWITCH) study explored the effects of sequential and combination therapy with denosumab and teriparatide. In this trial, the combination arm reached the peak in BMD faster than sequential treatment (teriparatide to denosumab) and achieved greater BMD values at cortical

skeletal sites. In summary, anabolic agents are associated with a significant reduction of fracture risk, but their use is restricted to 2 years and their discontinuation is associated with a decrease in BMD levels. Therefore, a prompt treatment with antiresorptive after bone anabolic agents is encouraged.

There is increasing evidence that anabolic treatment should be positioned in first line in patients at imminent risk of fracture and in patients at very-high risk of fracture.⁵⁹ In such patients, independently from BMD, anabolic treatment is cost-effective in certain regions and should be encouraged.⁶⁰ The approach of anabolic treatment positioned as first line in patients at high risk of fracture has been implemented in Italy since 2015 and other countries are now applying similar treatment reimbursement criteria.⁶¹ It is reasonable to think that, in the next decade, anabolic treatment will represent the first line of treatment in all patients with high or very high risk (i.e. fracture probability that lies above the upper assessment threshold after a FRAX assessment)⁵⁹ of fracture in most western countries.

Sequential treatment with antiresorptive agents might be required in selected patients. For example, patients, who after a long-term denosumab treatment achieve osteopenic BMD levels, might need a safe exit strategy to avoid the possible rebound effect (i.e. rapid decrease of BMD gain attained during denosumab treatment). Indeed, denosumab discontinuation has been associated with a rapid increase in bone turnover markers and, in some cases, with multiple vertebral fractures.^{62–64} Therefore, an exit strategy after denosumab treatment is highly recommended.⁶⁵ The rebound effect was shown to be attenuated in patients who were previously treated with bisphosphonates.^{66,67} Accordingly, younger patients with high bone turnover seems to be at greater risk of rebound after discontinuation.⁶⁸ Nevertheless, case reports and retrospective studies have shown that denosumab discontinuation was associated with multiple vertebral fractures even in patients previously exposed to bisphosphonates.^{69,70} In addition, a recent analysis on women that discontinued long-term denosumab therapy showed that the increase in bone turnover markers and Receptor activator of nuclear factor kappa-B ligand (RANKL) serum levels were directly related to the BMD gain during the treatment.⁷¹ This evidence supports the hypothesis of a pool of dormant osteoclast that are reactivated at the time

of denosumab discontinuation, and a potent bisphosphonate seems to be necessary to halt, or at least reduce, the rebound in bone turnover. Moreover, there may be clinically relevant differences in the timing of antiresorptive treatment after denosumab discontinuation. Reid and colleagues demonstrated that the bone loss after discontinuation is only partially prevented at 18 months by zoledronic acid administered 6 months after the last injection of denosumab. The same group of researchers tested the efficacy of a different timing of administration of zoledronic acid in preventing the bone loss following discontinuation. They found that a delayed administration of zoledronic acid was associated with preservation of BMD levels; in contrast, an 'early' administration of zoledronic acid after denosumab discontinuation was associated with BMD loss.⁷² Nevertheless, the study was largely underpowered to address the efficacy of different treatment strategies; moreover, the women under study were relatively young (63 ± 6 years), and most of them were treated with romosozumab prior to denosumab and all subjects in study received only 2 years of denosumab treatment. More recently, Anastasilakis *et al.*⁷³ reported the results of a randomized controlled trial of zoledronic acid for the prevention of the rebound effect after denosumab treatment cessation. In contrast with the results of the study by Reid *et al.*, Anastasilakis *et al.* reported a beneficial effect on BMD of a single infusion of zoledronic acid after denosumab discontinuation. Moreover, albeit not significant, an increase in BMD levels was seen in the zoledronic acid group at 12 months after randomization, a result that is controversial and diverges from other previously published experiences. In conclusion, to date, there are uncertainties regarding the most appropriate exit strategy following denosumab suspension. Large randomized and active-controlled clinical trials are warranted to further explore the topic.

Anabolic agent after an antiresorptive is perhaps the most common situation that clinicians face in their routine practice, especially when patients fracture during an antiresorptive treatment. To date, several studies reported data on the effects of anabolic treatment followed by an antiresorptive drug (bisphosphonate or denosumab).^{74–81}

In a recent observational study on long-term bisphosphonate users who switched to either teriparatide or denosumab,⁸¹ annualized BMD increase after switching to teriparatide was 1.3%

higher at the lumbar spine, and lower by 2.2% at the total hip and 1.1% at the femoral neck, compared with denosumab. However, pretreatment with different antiresorptive drugs might yield different results. In the study from Ettinger *et al.*,⁷⁴ in which patients received treatment with teriparatide after 18–36 months of either alendronate or raloxifene, prior treatment with alendronate was associated with a more than halved BMD gains at lumbar spine than raloxifene at 18 months (4.1% and 10.2%, respectively), while no benefit at all was seen in the alendronate pretreated group at the total hip site. Nevertheless, teriparatide treatment can effectively prevent clinical and radiographic fragility fractures even in patients previously treated with bisphosphonates.⁸² The VERtebral Fracture Treatment Comparisons in Osteoporotic Women (VERO) trial demonstrated that pretreatment with risedronate did not affect the efficacy of teriparatide in terms of fracture prevention. Interestingly, the crude incidence rate was the lowest in the risedronate to teriparatide group. Current evidence, mainly from the DATA-SWITCH study, does not support the use of anabolic agents after denosumab. In contrast, teriparatide and abaloparatide use after bisphosphonates seems to be safe and effective in reducing fracture's risk. Nevertheless, combined treatment with bone forming and antiresorptive agents seems to be the best strategy in patients at high risk of fracture.

Wnt pathway has emerged as the central regulator of bone metabolism and its major inhibitors sclerostin and Dickkopf (DKK)-1 have become target of great interest for the treatment of osteoporosis. Wnt is a natural stimulator osteoblasts function, and the inhibition of the inhibitors lead to stimulation of bone formation. Sclerostin inhibitors are now available for the treatment of osteoporosis and other metabolic bone diseases. Romosozumab, a sclerostin inhibitor, represents a new therapeutic option in the armamentarium of the bone specialists. Romosozumab has been shown to increase BMD rapidly and to reduce the risk of fracture to a greater extent than bisphosphonates.⁸³ Romosozumab use is restricted to a 12-month course and, upon its interruption, the effects on BMD are rapidly lost. Hence, an antiresorptive therapy is recommended after romosozumab discontinuation. It is interesting to note that romosozumab effect is not hampered by prior treatment with bisphosphonates or bone anabolics and seems to effectively reduce the rebound effect upon denosumab discontinuation.

Table 1. Novel imaging techniques for osteoporosis diagnosis and fracture risk^{34,39}.

Technique	Data acquisition	Advantages	Disadvantages	Radiation exposure (μ Sv)
DXA	Dual energy X-rays	Reference	Only BMD assessment	1–15
TBS	Post-processing DXA images	Strength analysis, estimate fracture risk independently from BMD	Availability, cost of software	1–15
FEA DXA	Post-processing DXA images	Strength analysis	Availability	1–15
HAL	Post-processing DXA images	Easily obtainable from DXA images	Not modifiable by therapy, not endorsed by international society for fracture risk assessment	1–15
HSA	Post-processing DXA images	Easily obtainable from DXA images	Not modifiable by therapy, not endorsed by international society for fracture risk assessment	1–15
REMS	Ultrasound	No radiation exposure, similar sensitivity and specificity to DXA, transportable instrument	Operator dependent	None
HRpQCT	CT scan	Qualitative and quantitative assessment, strength estimation, estimate fracture risk independently from BMD	Costs, availability, radiation exposure	50–100

BMD, bone mineral density; DXA, dual-energy X-ray absorptiometry; FEA, finite element analysis; HAL, hip-axis length; HSA, hip-strength analysis; HRpQCT, high-resolution peripheral quantitative computed tomography; REMS, radiofrequency echographic multi spectrometry; TBS, trabecular bone score.

Other sclerostin inhibitors are now on the pipeline and will likely be available within the next decade. Blosozumab is among the new sclerostin inhibitor in development, which phase III study results are expected within the next few years.⁸⁴ DKK-1 inhibitors are in development as well.⁸⁵ Although the initial enthusiasm around DKK-1 inhibitors, there has been raising safety potential concern due to the ubiquitous presence of DKK-1 in nonskeletal tissues. An animal study published in 2016 demonstrated that targeting both DKK-1 and sclerostin at the same time resulted in a synergistic effect on bone formation.⁸⁶ However, studies on humans are still missing. Nevertheless, the potentiality of dual inhibition (DKK-1 and sclerostin) is staggering. Dual inhibition was shown to enhance cortical bridging improving fracture repair to an extent that was not

considered possible before. Indeed, DKK-1 serum levels are increased in response to sclerostin inhibition, possibly explaining the closure of the anabolic window after 12 months of romo-sozumab. A similar feedback response has been demonstrated with teriparatide, in which the increase of DKK-1 can explain the waning of teriparatide effect on bone formation after 18–24 months.⁸⁷ As mentioned earlier, new molecules targeting miRNA are in study with promising preclinical results but no data on human beings are available to date. As an example, Wang *et al.* demonstrated that miR-214 can directly decrease bone formation and mineralization in animal models. In addition, the authors restored osteoblast activity in miR-214 transgenic, ovariectomized, and hindlimb-unloaded mice with antago-mir-214.⁸⁸ Remarkably, this anabolic approach

appeared to be not influenced by the coupling effect between osteoblasts and osteoclasts.

Pharmacological treatments are the mainstream of fracture prevention. Notwithstanding that, anti-osteoporotic medications can only reduce the risk of fracture with abolishing it; in addition, compliance to therapies is scarce. Therefore, complementary approaches are needed. Local osteo-enhancement procedure (LOEP) is an emerging surgical procedure that has been shown to effectively reduce the risk of re-fracture.⁸⁹ In synthesis, LOEP involves the implantation of an osteoconductive, calcium-based, material in the skeleton. The implant is rapidly incorporated and gives biomechanical benefit.⁹⁰ To date, LOEPs have been performed at femurs and vertebrae but, virtually, such procedures can be performed at any site.^{89,91} In 2020, a long-term prospective cohort study on LOEP was published.⁹² The authors treated 12 postmenopausal osteoporotic women with femoral LOEP and found that treated femoral neck BMD rapidly increased by 68% as soon as 3 months of follow-up. Interestingly, the FEA-estimated femoral strength increased by 41% in less than 6 months. The implant resorption and replacement with bone was nearly complete by 24 weeks. In January 2022, the completion of enrollment of the CONFIRM Europe Safety Study (CONFIRM) study has been announced. The study enrolled 60 subjects treated with LOEP and will provide additional evidence on the efficacy and safety of such procedure.

Conclusion

In summary, while osteoporosis is projected to cause millions of deaths worldwide in the upcoming future, we can face this anticipated crisis with novel diagnostic, prognostic, and therapeutic strategies. In the next decade, we will have broader access to novel and more precise methods of fracture risk prediction. Patients at high risk of fracture will be more commonly referred to the bone specialist for treatment thanks to the diffusion of FLS. Osteoporosis treatment will evolve, we will have more confidence with combined and sequential strategies, and we will have access to novel and innovative pharmacological therapies.

Author contributions

Giovanni Adami: Conceptualization; Project administration; Validation; Visualization; Writing – original draft; Writing – review & editing.

Angelo Fassio: Writing – review & editing.

Davide Gatti: Writing – review & editing.

Ombretta Viapiana: Writing – review & editing.

Camilla Benini: Writing – review & editing.

Maria I. Danila: Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Kenneth G. Saag: Writing – review & editing.

Maurizio Rossini: Supervision; Validation; Visualization; Writing – original draft; Writing – review & editing.

Conflict of interest statement

The authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: G.A. reports personal fees from Theramex and Galapagos outside the submitted work. A.F. reports personal fees from Abiogen, Novartis, and Neopharmed, outside the submitted work. D.G. has received advisory board honoraria, consultancy fees, and/or speaker fees from Abiogen, Celgene, Eli-Lilly, Neopharmed-Gentili, Pfizer, and UCB. M.I.D. reports research grants from Pfizer and Horizon. K.G.S. reports research grants from Amgen, Mereo, and Radius and has received consultancy fees from Amgen, outside the submitted work. O.V. has received advisory board honoraria and speaker fees from Gilead, Fresenius Kabi, Biogen, Ely-Lilly, UCB, AbbVie, MSD, and BMS. M.R. reports advisory board honoraria, consultancy fees, and/or speaker fees from AbbVie, Abiogen, Amgen, BMS, Eli-Lilly, Galapagos, Theramex, and UCB, outside the submitted work.

Funding

The authors received no financial support for the research, authorship, and/or publication of this article.

Competing interests

All authors have completed the ICMJE uniform disclosure form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare no conflicts of interest.

Compliance with ethical standard

The study was conducted according to the protocol 1876 approved by our local Ethics Committee, in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical

standards. Informed consent was waived because encrypted retrospective information was used.

Patient and public involvement statement

This research was done without patient involvement. Patients were not invited to comment on the review content. Patients were not invited to contribute to the writing or editing of this document for readability or accuracy.

ORCID iDs

Giovanni Adami  <https://orcid.org/0000-0002-8915-0755>

Kenneth G. Saag  <https://orcid.org/0000-0001-6189-8078>

Maurizio Rossini  <https://orcid.org/0000-0001-9692-2293>

Transparency declaration

The lead author (the manuscript's guarantor) affirms that the manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

References

1. Kanis JA, Borgström F, Compston J, *et al.* SCOPE: a scorecard for osteoporosis in Europe. *Arch Osteoporos* 2013; 8: 144.
2. Kanis JA, Norton N, Harvey NC, *et al.* SCOPE2021: a new scorecard for osteoporosis in Europe. *Arch Osteoporos* 2021; 16: 82.
3. Burge R, Dawson-Hughes B, Solomon DH, *et al.* Incidence and economic burden of osteoporosis-related fractures in the United States, 2005-2025. *J Bone Miner Res* 2007; 22: 465-475.
4. Wright NC, Looker AC, Saag KG, *et al.* The recent prevalence of osteoporosis and low bone mass in the United States based on bone mineral density at the femoral neck or lumbar spine. *J Bone Miner Res* 2014; 29: 2520-2526.
5. Johnell O and Kanis JA. An estimate of the worldwide prevalence and disability associated with osteoporotic fractures. *Osteoporos Int* 2006; 17: 1726-1733.
6. Khashayar P, Taheri E, Adib G, *et al.* Osteoporosis strategic plan for the Middle East and North Africa region. *Arch Osteoporos* 2019; 14: 20.
7. Adami G, Saag K, Mudano A, *et al.* Factors associated with the contemplative stage of readiness to initiate osteoporosis treatment. *Osteoporos Int* 2020; 31: 1283-1290.
8. Danila MI, Outman RC, Rahn EJ, *et al.* Evaluation of a multi-modal, direct-to-patient educational intervention targeting barriers to osteoporosis care: a randomized clinical trial. *J Bone Miner Res* 2018; 33: 763-772.
9. Danila MI, Outman RC, Rahn EJ, *et al.* A multi-modal intervention for Activating Patients at Risk for Osteoporosis (APROPOS): rationale, design, and uptake of online study intervention material. *Contemp Clin Trials Commun* 2016; 4: 14-24.
10. Jaleel A, Saag KG and Danila MI. Improving drug adherence in osteoporosis: an update on more recent studies. *Ther Adv Musculoskelet Dis* 2018; 10: 141-149.
11. Adami G, Gatti D, Rossini M, *et al.* Risk of fragility fractures in obesity and diabetes: a retrospective analysis on a nation-wide cohort. *Osteoporos Int* 2020; 31: 2113-2122.
12. Compston JE, Watts NB, Chapurlat R, *et al.* Obesity is not protective against fracture in postmenopausal women: glow. *Am J Med* 2011; 124: 1043-1050.
13. Bonds DE, Larson JC, Schwartz AV, *et al.* Risk of fracture in women with type 2 diabetes: the Women's Health Initiative Observational Study. *J Clin Endocrinol Metab* 2006; 91: 3404-3410.
14. McVeigh JA, Zhu K, Mountain J, *et al.* Longitudinal trajectories of television watching across childhood and adolescence predict bone mass at age 20 years in the Raine Study. *J Bone Miner Res* 2016; 31: 2032-2040.
15. Khomenko S, Cirach M, Pereira-Barboza E, *et al.* Premature mortality due to air pollution in European cities: a health impact assessment. *Lancet Planet Health* 2021; 5: e121-e134.
16. Adami G, Cattani G, Rossini M, *et al.* Association between exposure to fine particulate matter and osteoporosis: a population-based cohort study. *Osteoporos Int* 2022; 33: 169-176.
17. Nguyen TV. Air pollution: a largely neglected risk factor for osteoporosis. *Lancet Planet Health* 2017; 1: e311-e312.
18. Kanis JA, Melton LJ, Christiansen C, *et al.* The diagnosis of osteoporosis. *J Bone Miner Res* 1994; 9: 1137-1141.
19. Kanis JA, Harvey NC, Johansson H, *et al.* FRAX update. *J Clin Densitom* 2017; 20: 360-367.

20. Adami S, Bianchi G, Brandi ML, *et al.* Validation and further development of the WHO 10-year fracture risk assessment tool in Italian postmenopausal women: project rationale and description. *Clin Exp Rheumatol* 2010; 28: 561–570.
21. NIH Consensus Development Panel on Osteoporosis Prevention Diagnosis Therapy. Osteoporosis prevention, diagnosis, and therapy. *JAMA* 2001; 285: 785–795.
22. Adami G and Saag KG. Glucocorticoid-induced osteoporosis: 2019 concise clinical review. *Osteoporos Int* 2019; 30: 1145–1156.
23. Tang XL, Qin L, Kwok AW, *et al.* Alterations of bone geometry, density, microarchitecture, and biomechanical properties in systemic lupus erythematosus on long-term glucocorticoid: a case-control study using HR-pQCT. *Osteoporos Int* 2013; 24: 1817–1826.
24. Herrera S and Diez-Perez A. Clinical experience with microindentation in vivo in humans. *Bone* 2017; 95: 175–182.
25. Samelson EJ, Broe KE, Xu H, *et al.* Cortical and trabecular bone microarchitecture as an independent predictor of incident fracture risk in older women and men in the Bone Microarchitecture International Consortium (BoMIC): a prospective study. *Lancet Diabetes Endocrinol* 2019; 7: 34–43.
26. Martineau P, Leslie WD, Johansson H, *et al.* In which patients does lumbar spine trabecular bone score (TBS) have the largest effect? *Bone* 2018; 113: 161–168.
27. Martineau P, Leslie WD, Johansson H, *et al.* Clinical utility of using lumbar spine trabecular bone score to adjust fracture probability: the Manitoba BMD cohort. *J Bone Miner Res* 2017; 32: 1568–1574.
28. McCloskey EV, Odén A, Harvey NC, *et al.* A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. *J Bone Miner Res* 2016; 31: 940–948.
29. McCloskey EV, Odén A, Harvey NC, *et al.* Adjusting fracture probability by trabecular bone score. *Calcif Tissue Int* 2015; 96: 500–509.
30. Leslie WD, Lix LM, Morin SN, *et al.* Hip axis length is a FRAX- and bone density-independent risk factor for hip fracture in women. *J Clin Endocrinol Metab* 2015; 100: 2063–2070.
31. Beck TJ, Ruff CB, Warden KE, *et al.* Predicting femoral neck strength from bone mineral data. A structural approach. *Invest Radiol* 1990; 25: 6–18.
32. Khoo BCC, Lewis JR, Brown K, *et al.* Evaluation of a simplified hip structure analysis method for the prediction of incident hip fracture events. *Osteoporos Int* 2016; 27: 241–248.
33. Ha Y-C, Yoo J-I, Yoo J, *et al.* Effects of hip structure analysis variables on hip fracture: a propensity score matching study. *J Clin Med* 2019; 8: E1507.
34. Shepherd JA, Schousboe JT, Broy SB, *et al.* Executive summary of the 2015 ISCD position development conference on advanced measures from DXA and QCT: fracture prediction beyond BMD. *J Clin Densitom* 2015; 18: 274–286.
35. Viceconti M, Qasim M, Bhattacharya P, *et al.* Are CT-based finite element model predictions of femoral bone strength clinically useful? *Curr Osteoporos Rep* 2018; 16: 216–223.
36. Di Paola M, Gatti D, Viapiana O, *et al.* Radiofrequency echographic multispectrometry compared with dual X-ray absorptiometry for osteoporosis diagnosis on lumbar spine and femoral neck. *Osteoporos Int* 2019; 30: 391–402.
37. Adami G, Arioli G, Bianchi G, *et al.* Radiofrequency echographic multi spectrometry for the prediction of incident fragility fractures: a 5-year follow-up study. *Bone* 2020; 134: 115297.
38. Ciardo D, Pisani P, Lombardi FA, *et al.* Pos0163 incident fracture risk prediction using the fragility score calculated by lumbar spine radiofrequency echographic multi spectrometry (REMS) scans. *Ann Rheum Dis* 2021; 80: 294–294.
39. Diez-Perez A, Brandi ML, Al-Daghri N, *et al.* Radiofrequency echographic multi-spectrometry for the in-vivo assessment of bone strength: state of the art – outcomes of an expert consensus meeting organized by the European Society for Clinical and Economic Aspects of Osteoporosis, Osteoarthritis and Musculoskeletal Diseases (ESCEO). *Aging Clin Exp Res* 2019; 31: 1375–1389.
40. Ko N-Y, Chen L-R and Chen K-H. The role of micro RNA and long-non-coding RNA in osteoporosis. *Int J Mol Sci* 2020; 21: E4886.
41. Yang Y, Yujiao W, Fang W, *et al.* The roles of miRNA, lncRNA and circRNA in the development of osteoporosis. *Biol Res* 2020; 53: 40.
42. Zuo B, Zhu J, Li J, *et al.* microRNA-103a functions as a mechanosensitive microRNA to inhibit bone formation through targeting Runx2. *J Bone Miner Res* 2015; 30: 330–345.
43. Öhman-Mägi C, Holub O, Wu D, *et al.* Density and mechanical properties of vertebral trabecular bone – a review. *JOR Spine* 2021; 4: e1176.

44. Turner RT. Skeletal adaptation to external loads optimizes mechanical properties: fact or fiction. *Curr Opin Orthop* 2001; 12: 384–388.
45. Lam SCB, Wald MJ, Rajapakse CS, *et al.* Performance of the MRI-based virtual bone biopsy in the distal radius: serial reproducibility and reliability of structural and mechanical parameters in women representative of osteoporosis study populations. *Bone* 2011; 49: 895–903.
46. Hippisley-Cox J and Coupland C. Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractureScores. *BMJ* 2009; 339: b4229.
47. Papadakis GZ, Karantanas AH, Tsiknakis M, *et al.* Deep learning opens new horizons in personalized medicine (Review). *Biomed Rep* 2019; 10: 215–217.
48. Tanphiriyakun T, Rojanasthien S and Khumrin P. Bone mineral density response prediction following osteoporosis treatment using machine learning to aid personalized therapy. *Sci Rep* 2021; 11: 13811.
49. Iliou T, Anagnostopoulos C-N and Anastassopoulos G. Osteoporosis detection using machine learning techniques and feature selection. *Int J Artif Intell Tools* 2014; 23: 1450014.
50. Ordóñez C, Matías JM, de Cos Juez JF, *et al.* Machine learning techniques applied to the determination of osteoporosis incidence in postmenopausal women. *Math Comput Model* 2009; 50: 673–679.
51. Cruz AS, Lins HC, Medeiros RVA, *et al.* Artificial intelligence on the identification of risk groups for osteoporosis, a general review. *Biomed Eng Online* 2018; 17: 12.
52. Leslie WD, Giangregorio LM, Yogendran M, *et al.* A population-based analysis of the post-fracture care gap 1996–2008: the situation is not improving. *Osteoporos Int* 2012; 23: 1623–1629.
53. Ganda K. Fracture liaison services: past, present and future. *Osteoporos Int* 2021; 32: 1461–1464.
54. Li N, Hilgsmann M, Boonen A, *et al.* The impact of fracture liaison services on subsequent fractures and mortality: a systematic literature review and meta-analysis. *Osteoporos Int* 2021; 32: 1517–1530.
55. Wu C-H, Tu S-T, Chang Y-F, *et al.* Fracture liaison services improve outcomes of patients with osteoporosis-related fractures: a systematic literature review and meta-analysis. *Bone* 2018; 111: 92–100.
56. Majumdar SR, McAlister FA, Johnson JA, *et al.* Comparing strategies targeting osteoporosis to prevent fractures after an upper extremity fracture (C-STOP Trial): a randomized controlled trial. *J Bone Miner Res* 2018; 33: 2114–2121.
57. Black DM, Bilezikian JP, Ensrud KE, *et al.* One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis. *N Engl J Med* 2005; 353: 555–565.
58. Bone HG, Cosman F, Miller PD, *et al.* ACTIVEExtend: 24 months of alendronate after 18 months of abaloparatide or placebo for postmenopausal osteoporosis. *J Clin Endocrinol Metab* 2018; 103: 2949–2957.
59. Kanis JA, Harvey NC, McCloskey E, *et al.* Algorithm for the management of patients at low, high and very high risk of osteoporotic fractures. *Osteoporos Int* 2020; 31: 1–12.
60. Li N, Cornelissen D, Silverman S, *et al.* An updated systematic review of cost-effectiveness analyses of drugs for osteoporosis. *Pharmacoeconomics* 2021; 39: 181–209.
61. Adami G, Rossini M, Fassio A, *et al.* Comments on Kanis *et al.*: algorithm for the management of patients at low, high, and very high risk of osteoporotic fractures. *Osteoporos Int* 2020; 31: 1015.
62. Bone HG, Bolognese MA, Yuen CK, *et al.* Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. *J Clin Endocrinol Metab* 2011; 96: 972–980.
63. Cummings SR, Ferrari S, Eastell R, *et al.* Vertebral fractures after discontinuation of denosumab: a post hoc analysis of the randomized placebo-controlled FREEDOM trial and its extension. *J Bone Miner Res* 2018; 33: 190–198.
64. Anastasilakis AD, Polyzos SA, Makras P, *et al.* Clinical features of 24 patients with rebound-associated vertebral fractures after denosumab discontinuation: systematic review and additional cases. *J Bone Miner Res* 2017; 32: 1291–1296.
65. Tsourdi E, Langdahl B, Cohen-Solal M, *et al.* Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. *Bone* 2017; 105: 11–17.
66. Tsourdi E, Makras P, Rachner TD, *et al.* Denosumab effects on bone density and turnover in postmenopausal women with low bone mass with or without previous treatment. *Bone* 2019; 120: 44–49.
67. Uebelhart B, Rizzoli R and Ferrari SL. Retrospective evaluation of serum CTX levels

- after denosumab discontinuation in patients with or without prior exposure to bisphosphonates. *Osteoporos Int* 2017; 28: 2701–2705.
68. Aubry-Rozier B, Liebich G, Stoll D, *et al.* Op0085 can we avoid the loss of bone mineral density one year after denosumab discontinuation? The reolaus bone project. *Ann Rheum Dis* 2019; 78: 115.
 69. Lamy O, Fernández-Fernández E, Monjo-Henry I, *et al.* Alendronate after denosumab discontinuation in women previously exposed to bisphosphonates was not effective in preventing the risk of spontaneous multiple vertebral fractures: two case reports. *Osteoporos Int* 2019; 30: 1111–1115.
 70. Tripto-Shkolnik L, Rouach V, Marcus Y, *et al.* Vertebral fractures following denosumab discontinuation in patients with prolonged exposure to bisphosphonates. *Calcif Tissue Int* 2018; 103: 44–49.
 71. Fassio A, Adami G, Benini C, *et al.* Changes in Dkk-1, sclerostin, and RANKL serum levels following discontinuation of long-term denosumab treatment in postmenopausal women. *Bone* 2019; 123: 191–195.
 72. Horne AM, Mihov B and Reid IR. Effect of zoledronate on bone loss after romosozumab/denosumab: 2-year follow-up. *Calcif Tissue Int* 2019; 105: 107–108.
 73. Anastasilakis AD, Papapoulos SE, Polyzos SA, *et al.* Zoledronate for the prevention of bone loss in women discontinuing denosumab treatment. *J Bone Miner Res* 2019; 34: 2220–2228.
 74. Ettinger B, San Martin J, Crans G, *et al.* Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate. *J Bone Miner Res* 2004; 19: 745–751.
 75. Miller PD, Delmas PD, Lindsay R, *et al.* Early responsiveness of women with osteoporosis to teriparatide after therapy with alendronate or risedronate. *J Clin Endocrinol Metab* 2008; 93: 3785–3793.
 76. Boonen S, Marin F, Obermayer-Pietsch B, *et al.* Effects of previous antiresorptive therapy on the bone mineral density response to two years of teriparatide treatment in postmenopausal women with osteoporosis. *J Clin Endocrinol Metab* 2008; 93: 852–860.
 77. Cosman F, Wermers RA, Recknor C, *et al.* Effects of teriparatide in postmenopausal women with osteoporosis on prior alendronate or raloxifene: differences between stopping and continuing the antiresorptive agent. *J Clin Endocrinol Metab* 2009; 94: 3772–3780.
 78. Leder BZ, Tsai JN, Uihlein AV, *et al.* Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): extension of a randomised controlled trial. *Lancet* 2015; 386: 1147–1155.
 79. Obermayer-Pietsch BM, Marin F, McCloskey EV, *et al.* Effects of two years of daily teriparatide treatment on BMD in postmenopausal women with severe osteoporosis with and without prior antiresorptive treatment. *J Bone Miner Res* 2008; 23: 1591–1600.
 80. Jakob F, Oertel H, Langdahl B, *et al.* Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study. *Eur J Endocrinol* 2012; 166: 87–97.
 81. Lyu H, Zhao SS, Yoshida K, *et al.* Comparison of teriparatide and denosumab in patients switching from long-term bisphosphonate use. *J Clin Endocrinol Metab* 2019; 104: 5611–5620.
 82. Geusens P, Marin F, Kendler DL, *et al.* Effects of teriparatide compared with risedronate on the risk of fractures in subgroups of postmenopausal women with severe osteoporosis: the VERO trial. *J Bone Miner Res* 2018; 33: 783–794.
 83. Saag KG, Petersen J, Brandi ML, *et al.* Romosozumab or alendronate for fracture prevention in women with osteoporosis. *N Engl J Med* 2017; 377: 1417–1427.
 84. Recker RR, Benson CT, Matsumoto T, *et al.* A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. *J Bone Miner Res* 2015; 30: 216–224.
 85. Li X, Grisanti M, Fan W, *et al.* Dickkopf-1 regulates bone formation in young growing rodents and upon traumatic injury. *J Bone Miner Res* 2011; 26: 2610–2621.
 86. Florio M, Gunasekaran K, Stolina M, *et al.* A bispecific antibody targeting sclerostin and DKK-1 promotes bone mass accrual and fracture repair. *Nat Commun* 2016; 7: 11505.
 87. Gatti D, Viapiana O, Idolazzi L, *et al.* The waning of teriparatide effect on bone formation markers in postmenopausal osteoporosis is associated with increasing serum levels of DKK1. *J Clin Endocrinol Metab* 2011; 96: 1555–1559.
 88. Wang X, Guo B, Li Q, *et al.* miR-214 targets ATF4 to inhibit bone formation. *Nat Med* 2013; 19: 93–100.
 89. Shaul JL, Hill RS, Boussein ML, *et al.* AGN1 implant material to treat bone loss: resorbable implant forms normal bone with and without

alendronate in a canine critical size humeral defect model. *Bone* 2022; 154: 116246.

90. Stronck JD, Shaul JL, Favell D, *et al.* In vitro injection of osteoporotic cadaveric femurs with a triphasic calcium-based implant confers immediate biomechanical integrity. *J Orthop Res* 2019; 37: 908–915.
91. Trost M, Schmoelz W, Wimmer D, *et al.* Local osteo-enhancement of osteoporotic vertebra with a triphasic bone implant material increases

strength – a biomechanical study. *Arch Orthop Trauma Surg* 2020; 140: 1395–1401.

92. Howe JG, Hill RS, Stronck JD, *et al.* Treatment of bone loss in proximal femurs of postmenopausal osteoporotic women with AGN1 local osteo-enhancement procedure (LOEP) increases hip bone mineral density and hip strength: a long-term prospective cohort study. *Osteoporos Int* 2020; 31: 921–929.

Visit SAGE journals online
[journals.sagepub.com/
home/tab](https://journals.sagepub.com/home/tab)

 SAGE journals